Harte Hanks (HHS) Cash & Equivalents (2010 - 2026)

Harte Hanks (HHS) has reported Cash & Equivalents for 17 consecutive years, with $4.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 49.48% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $4.5 million (down 49.48% YoY), while the FY2025 annual figure was $5.6 million, down 43.76% from the prior year.
• Cash & Equivalents eased to $4.5 million in Q1 2026 per HHS's latest filing, from $5.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $18.9 million in Q4 2023 and bottomed at $4.5 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $9.7 million across 5 years, with a median of $9.9 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 63.57% — and 2023, when it surged 92.38%.
• Harte Hanks' Cash & Equivalents stood at $10.4 million in 2022, then surged by 82.01% to $18.9 million in 2023, then sank by 47.34% to $9.9 million in 2024, then slumped by 43.76% to $5.6 million in 2025, then decreased by 18.78% to $4.5 million in 2026.
• Business Quant data shows HHS's Cash & Equivalents at $4.5 million in Q1 2026, $5.6 million in Q4 2025, and $6.5 million in Q3 2025.